ACADEMISCH ZIEKENHUIS LEIDEN

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 27228
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 25142
 
  
 
C07K PEPTIDES 19117
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 1089
 
  
 
C12Q MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS 7118
 
  
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 7199
 
  
 
A61B DIAGNOSIS; SURGERY; IDENTIFICATION 3237
 
  
 
A01N PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF 293
 
  
 
A61L METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES 269
 
  
 
A61M DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY 1153

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2017/0253,658 CD94/NKG2A AND/OR CD94/NKG2B ANTIBODY, VACCINE COMBINATIONSAug 28, 15Sep 07, 17[A61K, C07K]
2017/0254,865 A MAGNETIC RESONANCE APPARATUS COMPRISING A PLASMA ANTENNASep 15, 15Sep 07, 17[H01Q, G01R]
2017/0143,818 INTRADERMAL HPV PEPTIDE VACCINATIONDec 16, 16May 25, 17[A61K, C12N]
2017/0107,512 METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNADec 27, 16Apr 20, 17[C12N]
2014/0039,037 ANTISENSE OLIGONUCLEOTIDE DIRECTED REMOVAL OF PROTEOLYTIC CLEAVAGE SITES, THE HCHWA-D MUTATION, AND TRINUCLEOTIDE REPEAT EXPANSIONSOct 07, 13Feb 06, 14[C12N]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9896687 Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structureSep 21, 05Feb 20, 18[C07H, A61K, C12Q, C12N, G01N]
9883869 Tool head assembly and associated apparatusNov 11, 14Feb 06, 18[A61B, B23D]
9695481 Polynucleotides comprising a reporter sequence operatively linked to a regulatory elementSep 15, 11Jul 04, 17[C12Q, C12N, C07K]
9650423 Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responsesAug 21, 15May 16, 17[A61K, C12N, C07K]
9632084 Anti-carbamylated protein antibodies and the risk for arthritisFeb 01, 12Apr 25, 17[G01N]
9623103 Arterivirus protein and expression mechanismsJul 18, 13Apr 18, 17[A61K, C12N, G06F, C07K]
9611471 Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteinsAug 04, 11Apr 04, 17[C12N]
9562075 Intradermal HPV peptide vaccinationMay 27, 08Feb 07, 17[A61K, C12N, C07K]
9562085 Antimicrobial peptideMay 09, 14Feb 07, 17[A61K, C07K, A61L]
9528109 Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNANov 14, 14Dec 27, 16[A61K, C07H, C12N]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
2016/0355,810 Modulation of Exon Recognition in Pre-mRNA By Interfering with the Secondary RNA StructureAbandonedApr 14, 16Dec 08, 16[C12Q, C12N, G01N]
2016/0304,864 MEANS AND METHODS FOR COUNTERACTING MUSCLE DISORDERSAbandonedJan 07, 16Oct 20, 16[A61K, C12N]
2016/0067,269 Miltefosin Or Perifosin For Use In The Treatment of IBDAbandonedApr 08, 14Mar 10, 16[A61K]
2014/0378,527 MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTUREAbandonedJun 24, 14Dec 25, 14[C12N]
2014/0357,698 MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTUREAbandonedJun 03, 14Dec 04, 14[C12N]
2014/0357,855 MODULATION OF EXON RECOGNITION IN PRE-MRNA BY INTERFERING WITH THE SECONDARY RNA STRUCTUREAbandonedJun 03, 14Dec 04, 14[C12N]
2014/0274,956 LIPIDOMICS OF FAMILIAL LONGEVITYAbandonedMar 13, 14Sep 18, 14[H01J, A61K, G01N]
2014/0221,458 METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNAAbandonedMar 07, 14Aug 07, 14[C12N]
2014/0128,592 METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNAAbandonedDec 19, 13May 08, 14[C12N]
2014/0113,955 METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNAAbandonedDec 04, 13Apr 24, 14[C12N]
2014/0088,174 COMPOUNDS AND METHODS FOR ALTERING ACTIVIN RECEPTOR-LIKE KINASE SIGNALINGAbandonedApr 05, 12Mar 27, 14[C12N]
8663646 P53 peptide vaccineExpiredDec 03, 09Mar 04, 14[A61K]
8404647 Peptidylarginine deiminase (PAD) inhibitorsExpiredDec 10, 10Mar 26, 13[A61K]
2012/0270,930 METHODS AND COMPOSITIONS FOR DYSFERLIN EXON-SKIPPINGAbandonedOct 29, 09Oct 25, 12[A61K, C07H, C12Q, C12N]
2012/0172,255 ES-MS OF GLYCOPEPTIDES FOR ANALYSIS OF GLYCOSYLATIONAbandonedSep 03, 10Jul 05, 12[C12Q, C40B]
2011/0311,525 DELIVERY OF A CD40 AGONIST TO A TUMOR DRAINING LYMPH NODE OF A SUBJECTAbandonedAug 31, 09Dec 22, 11[A61K, A61P]
2011/0263,682 METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53AbandonedApr 26, 11Oct 27, 11[A61K, C07H, C12N, A61P]
8029998 Genetic markers for prognosis of antifolate treatment efficacyExpiredJul 31, 08Oct 04, 11[C12Q, C12P]
2011/0053,149 METHYLATION DETECTION IN THE GENOMIC REGION OF A RECEPTOR PROTEINTYROSINE PHOSPHATASE GAMMA GENE FOR DETECTION AND/OR DIAGNOSIS OF A TUMOURAbandonedDec 29, 08Mar 03, 11[C12Q]
2011/0053,835 ANTIMICROBIAL PEPTIDES DERIVED FROM CAP18AbandonedSep 14, 10Mar 03, 11[A61K, A61P]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.